Format

Send to

Choose Destination
Mitochondrion. 2007 Jun;7 Suppl:S154-67. Epub 2007 Mar 16.

Coenzyme Q10 in cardiovascular disease.

Author information

1
CJOB Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia.

Abstract

In this review we summarise the current state of knowledge of the therapeutic efficacy and mechanisms of action of CoQ(10) in cardiovascular disease. Our conclusions are: 1. There is promising evidence of a beneficial effect of CoQ(10) when given alone or in addition to standard therapies in hypertension and in heart failure, but less extensive evidence in ischemic heart disease. 2. Large scale multi-centre prospective randomised trials are indicated in all these areas but there are difficulties in funding such trials. 3. Presently, due to the notable absence of clinically significant side effects and likely therapeutic benefit, CoQ(10) can be considered a safe adjunct to standard therapies in cardiovascular disease.

PMID:
17485243
DOI:
10.1016/j.mito.2007.02.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center